US doctors reconsider Pfizer’s Paxlovid for lower-risk COVID patients
May 28 (Reuters) – Use of Pfizer Inc’s (PFE.N) COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a US public health agency warned symptoms could return after people finish are a course of the drug, and that they then have to isolate a second time. More … Read more